News |  Contact |  Sitemap |  Disclaimer | 
About us  |   Services  |   Territories  |   Partners  |  
Throughout the centuries Slovenia has been invaded from north, south, east and west, but now this small country, only half the size of Switzerland, has gained its independence, joined the European Union and introduced the euro. - All in the last 20 years. 
The rather cautious handling of political and economic reform has allowed for a smooth transformation, which has paid off for the country. As per capita GDP of 17.500 € robust economic growth, modest budget deficits and a stable currency provide an attractive environment both for investors and marketers.
Slovenia's per capita expenditure on pharmaceuticals is clearly highest among Central European countries, whereas imported drugs account for approx. 2/3 of the consumption. The majority of standard preparations enjoy reimbursement at prices not far below European levels. Thus, the small country offers interesting perspectives for foreign companies despite the presence of two major local players.
The regulatory system is harmonised with the EU legislation.


Key facts and figures:


Area:   20'273 km2
Capital:   Ljubljana
Population:   2,06 million (2016)
Currency:   Euro (EUR)
Volume of pharmaceutical market:   EUR 594,4 million (2015)
Of which imported drugs:   80%
No. of hospitals:   26
No. of physicians:   5'140 (2,5/1000 inhabitants)
No. of pharmacies:   326 outpatient
Our subsidiary:   Ewopharma d.o.o.
    Cesta 24. Junija 23
    SI-1231 Ljubljana
Phone: +386 590 848 40
Fax: +386 590 848 49
Administration 1
Sales and Marketing 16